How I treat patients with advanced systemic mastocytosis
- 23 December 2010
- journal article
- Published by American Society of Hematology in Blood
- Vol. 116 (26), 5812-5817
- https://doi.org/10.1182/blood-2010-08-292144
Abstract
Advanced systemic mastocytosis (SM) is a rare myeloid neoplasm characterized by uncontrolled accumulation of neoplastic mast cells (MCs) in various organs with consecutive impairment of organ function, drug resistance, and a poor prognosis. Advanced SM may present as smoldering or slowly progressing neoplasm but may also present as rapidly progressing aggressive SM or even as MC leukemia. Approximately half of the patients have an associated hematologic non–MC-lineage disease (SM-AHNMD) or develop an AHNMD over time. Drug resistance may not only result from the KIT mutant D816V that is found in most patients, but also from KIT-independent pro-oncogenic signaling pathways that play a role in disease evolution. In patients with slow progression, advanced SM can often be kept under control for months with interferon-α or 2CdA. By contrast, in rapidly progressing aggressive SM and MC leukemia, even polychemotherapy and hematopoietic stem cell transplantation may fail, which points to the need to develop new drugs and treatment concepts for these patients. In SM-AHNMD, separate treatment plans should be established for the SM component and the AHNMD component of the disease, with recognition that the AHNMD often has to be managed and treated as a secondary and thus a high-risk neoplasm.This publication has 48 references indexed in Scilit:
- Aberrant expression of CD30 in neoplastic mast cells in high-grade mastocytosisLaboratory Investigation, 2011
- In vitro and in vivo growth-inhibitory effects of cladribine on neoplastic mast cells exhibiting the imatinib-resistant KIT mutation D816VExperimental Hematology, 2010
- Differential Diagnoses of Systemic Mastocytosis in Routinely Processed Bone Marrow Biopsy Specimens: A ReviewPathobiology, 2010
- High frequency of concomitant mastocytosis in patients with acute myeloid leukemia exhibiting the transforming KIT mutation D816VMolecular Oncology, 2010
- Variable presence of KITD816V in clonal haematological non‐mast cell lineage diseases associated with systemic mastocytosis (SM–AHNMD)The Journal of Pathology, 2009
- Mast cells and mastocytosisBlood, 2008
- Systemic Mastocytosis Associated with Chronic Idiopathic Myelofibrosis: A Distinct Subtype of Systemic Mastocytosis-Associated Clonal Hematological Nonmast Cell Lineage Disorder Carrying the Activating Point Mutations KITD816V and JAK2V617FThe Journal of Molecular Diagnostics, 2008
- FIP1L1/PDGFRA is a molecular marker of chronic eosinophilic leukaemia but not for systemic mastocytosisEuropean Journal of Clinical Investigation, 2007
- Response to Interferon Alfa-2b in a Patient with Systemic MastocytosisThe New England Journal of Medicine, 1992
- The Liver, Spleen, and Lymph Nodes in MastocytosisJournal of Investigative Dermatology, 1991